TABLE: Jetrea, RoActemra win over Scots; five others rejected
This article was originally published in Scrip
Executive Summary
In an unusually negative round of decisions, Scotland's health technology appraisal institute, the Scottish Medicines Consortium (SMC), has given its approval to just two out of the seven drugs under review this month. Only Thrombogenics and Roche were able to impress, with Jetrea (ocriplasmin) and subcutaneous RoActemra (tocilizumab) respectively.